Kinetics of Biomarkers in Acute Pyelonephritis

Kinetics of Procalcitonin, C-reactive Protein and Pyuria in Uncomplicated Pyelonephritis in Women: A Pilot Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00805181

Enrollment

Registered

2008-12-09

Start date

2008-12-31

Completion date

2010-04-30

Last updated

2010-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pyelonephritis

Brief summary

The objective of this study is to explore the kinetics of biomarkers in 30 adult female patients with uncomplicated acute pyelonephritis.

Detailed description

We will measure c-reactive protein, procalcitonin, pyuria and a new blood biomarker (Signature TM) everyday till normalization of these markers in 30 adult female patients with uncomplicated acute pyelonephritis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \> 18 years * Flank/loin pain or tenderness, or both and fever \> 38°C during the last 48 hours and pyuria

Exclusion criteria

* Pregnancy * Presence of indwelling catheters * Known polycystic kidney disease or any malformation of the urinary tract, or single kidney; renal transplant recipients; acute or chronic renal failure requiring dialysis * Recent discharge from hospital (during the last 10 days); ongoing antibiotic treatment * Known severe immunosuppression: Receiver of solid-organ or hematopoietic stem cells transplants; neutropenia ( \< 1 G neutrophils / L); chronic (more than 14 days) use of systemic glucocorticoids (\>10 mg/d of prednisone); active use of immunosuppressive therapy for the treatment of auto-immune or inflammatory disease; HIV infection with \< 350 CD4+ cells / ml or unknown CD4+ status * Pyelonephritis initially identified as complicated: obstruction of urinary tract, urinary stone; history of renal infection in the last 15 days * Patient with severe sepsis or septic shock

Design outcomes

Primary

Measure	Time frame
Blood and urine biomarkers (procalcitonin, C-reactive protein, SIGNATURE(TM) test, pyuria	Daily till day 15.

Countries

Switzerland

Outcome results